Bridging the gap between innovation and capital
MRL Ventures Fund
Focus on Biotech Therapeutic Companies
Program
MRL Ventures Fund (MRLV) partners with visionary founders pursuing breakthrough innovations and medicines to transform patient care. MRVL invests globally in early-stage, preclinical therapeutics companies by providing capital, strategic guidance, and access to Merck’s deep domain expertise to accelerate development of breakthrough therapeutics from concept to clinic.
Event
LaunchBio, Citrin Cooperman, and Silicon Valley Bank, a Division of First Citizens Bank, with support by Fondation Ipsen, are pleased to announce their next Investor Connect virtual event with MRL Ventures Fund (MRLV).
MRLV backs exceptional science across all modalities – from small molecules to cell therapies – providing committed capital and board-level partnership to early-stage (including seed-stage) companies. Its mission is finding and funding imaginative scientists and entrepreneurs who are advancing differentiated, high-quality breakthrough therapeutics.
Applications will be selected based on meeting the following criteria:
Geography
Open to investments globally
Company type
Early-stage biotech companies focused on preclinical therapeutics companies
Modalities of Interest
- Small molecules
- Biologics
- Protein and RNA-based therapeutics
- Gene therapies and Gene editing technologies
- Cell therapies
- Regenerative medicine
- Vaccines
- Microbiome & engineered living therapies
- Radiopharmaceuticals
- Oncolytic viruses
Therapeutic areas include, but are not limited to:
- Cardiology
- Endocrinology
- Gastroenterology
- Hematology
- Immunology
- Neurology
- Oncology
- Ophthalmology
- Pulmonology
Stage
Companies seeking funding for Seed, Series A and Series B
Qualifying start-ups can apply here today.
Applications are accepted on a rolling basis. Learn more about LaunchBio’s Investor Connect series, in partnership with Citrin Cooperman and Silicon Valley Bank, a division of First Citizens Bank.